SCHEMBL14745148

SCHEMBL14745148

CCc1cc(C(=O)OC)c(=O)n(Cc2ccc(OC)cc2OC)c1-c1ccc2c(c1)cc(C1CCN(C(=O)OC(C)(C)C)C1)n2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
PDE4B Q07343 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
AADAT Q8N5Z0 1/20 0.38
TSHR P16473 2/20 0.37
MAPK1 P28482 1/20 0.37
STS P08842 1/20 0.37
EPHX2 P34913 1/20 0.37
KMT2A Q03164 3/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 2/20 0.37
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TP53 P04637 1/20 0.36
PIK3CA P42336 1/20 0.36
PRKDC P78527 1/20 0.36
P2RX3 P56373 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745044 0.94 KMT2A (0.41) MAPTPDE4BKDM4EALDH1A1HPGD
SCHEMBL14745171 0.88 MAPT (0.37) MAPTPDE4BKDM4EALDH1A1HPGD
SCHEMBL14744918 0.85 AADAT (0.38) MAPTPDE4BKDM4EALDH1A1HPGD
SCHEMBL14744953 0.80 LMNA (0.39) KDM4EALDH1A1AADATTSHRMAPK1
SCHEMBL14745624 0.79 GABRG2 (0.40) MAPTALDH1A1TP53
SCHEMBL14745444 0.79 LMNA (0.40) MAPTKDM4EALDH1A1AADATTSHR
SCHEMBL14745399 0.78 LMNA (0.37) MAPTALDH1A1AADATTSHRMAPK1
SCHEMBL14745369 0.78 L3MBTL1 (0.39) MAPTALDH1A1MAPK1KMT2AMEN1
SCHEMBL14745593 0.78 GABRG2 (0.39) MAPTKDM4EALDH1A1TP53
SCHEMBL14745992 0.77 L3MBTL1 (0.35) MAPTALDH1A1AADATTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP MAPT 4110/4885PDE4B 3185/4885KDM4E 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.